Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature

Thromb Haemost. 2020 Jul;120(7):1096-1107. doi: 10.1055/s-0040-1712957. Epub 2020 Jun 22.

Abstract

Background: Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatments, and only a few large patient cohorts have been reported. In this study, biological and clinical data from 144 French patients with HIT were analyzed in comparison with the literature.

Methods: The diagnosis of HIT was confirmed in all patients by an immunoassay combined with serotonin release assay. In the literature, only cohorts of at least 20 HIT patients published from 1992 were selected for a comparative analysis.

Results: Two-thirds of patients were hospitalized in surgery and most were treated with unfractionated heparin (83.2% vs. 16.8% with low molecular weight heparin only). Thrombotic events in 54 patients (39.7%) were mainly venous (41/54). However, arterial thrombosis was more frequent after cardiac surgery (13.2% vs. 2.4% in other surgeries, p = 0.042) with a shorter recovery time (median = 3 vs. 5 days, p < 0.001). The mortality rate was lower in our series than in the 22 selected published studies (median = 6.3% vs. 15.9%). Three genetic polymorphisms were also studied and homozygous subjects FcγRIIA RR were more frequent in patients with thrombosis (37.8 vs. 18.2% in those without thrombosis, p = 0.03).

Conclusion: This study shows that the mortality rate due to HIT has recently decreased in France, possibly due to earlier diagnosis and improved medical care. It also confirms the strong association between polymorphism FcγRIIA H131R and thrombosis in HIT.

Publication types

  • Comparative Study
  • Multicenter Study
  • Systematic Review

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects*
  • Antigens, Human Platelet / genetics
  • Female
  • France
  • Heparin / adverse effects*
  • Humans
  • Integrin beta3 / genetics
  • Male
  • Middle Aged
  • Platelet Endothelial Cell Adhesion Molecule-1 / genetics
  • Polymorphism, Genetic
  • Prognosis
  • Prospective Studies
  • Receptors, IgG / genetics
  • Risk Assessment
  • Risk Factors
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / diagnosis
  • Thrombocytopenia / mortality
  • Thrombocytopenia / therapy
  • Time Factors
  • Young Adult

Substances

  • Anticoagulants
  • Antigens, Human Platelet
  • FCGR2A protein, human
  • ITGB3 protein, human
  • Integrin beta3
  • PECAM1 protein, human
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Receptors, IgG
  • human platelet antigen 1b
  • Heparin

Grants and funding